close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information

NEW YORK, January 04, 2008 /PRNewswire/ -- Berkery Noyes announced today that the firm represented The Thomson Corporation in the sale of CenterWatch ("CW") and New England Institutional Review Board ("NEIRB") to Jobson Medical Information, a portfolio company of The Wicks Group, LLC. Terms of the transaction were not disclosed.

Founded in 1994, CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients. As a pioneer in publishing clinical trials information, CenterWatch was the first Internet site to publish detailed information about active clinical trials that could be assessed by patients and their advocates.

The NEIRB division provides FDA mandated services to pharmaceutical companies and Contract Research Organizations (CRO's). Founded in 1988, NEIRB was one of the first central institutional review boards established to meet the ethical review needs of a burgeoning drug development market.

"Both CW and NEIRB are winning franchises in the healthcare market and both have high caliber management and employees," said Tom O'Connor, the Berkery Noyes Managing Director who managed the transaction on behalf of The Thomson Corporation. "Within Jobson Medical Information portfolio these assets can grow and expand," added O'Connor.

Berkery Noyes acted as exclusive financial advisor to The Thomson Corporation on the sale of CenterWatch and NEIRB. Berkery Noyes has been involved with many of the most notable transactions in the healthcare, pharmaceutical tools and services, and medical marketing sectors involving both strategic and financial buyers and sellers.

About Berkery Noyes -- Berkery Noyes is one of the pre-eminent merger and acquisition firms serving the information industry, having completed more than 400 transactions since its inception. Among the most recent transactions completed by Berkery Noyes are the sale of HMP Communications to Alta Communications in partnership with Paul Mackler and Ken Fisher, the sale of Complete Healthcare Communications to MediMedia a portfolio company of Vestar Capital Partners, the divesture by The Thomson Corporation of American Health Consultants to Thompson Publishing Group; acquisition by Springer Science + Business Media of Current Medicine Group; acquisition by WebMd Corporation of Conceptis; acquisition by The Wicks Group of DesignWrite, Inc. and the acquisition by Veronis Suhler Stevenson of Facts On File.

Berkery Noyes' clients include private companies seeking a buyer, most of the major international information companies, and private equity firms who use the firm's expertise in locating, analyzing and negotiating with acquisition candidates and in managing divestitures. The firm operates with a staff of forty professionals serving the information and publishing industry. For more information, visit www.berkerynoyes.com.

About CenterWatch -- www.centerwatch.com

About New England Institutional Review Board -- www.neirb.com

CONTACT: Tom O'Connor, Managing Director, +1-646-442-7994, or John Shea,Chief Operating Officer, +1-212-668-3022, both of Berkery Noyes

Web site: http://www.berkerynoyes.com/http://www.centerwatch.com/http://www.neirb.com/

Ticker Symbol: (NYSE:TOC),(Toronto:TOC.)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...